2023 Interim Results Earnings Call
Hua Medicine
Aug 25, 2023
1811

Friday August 25,2023

calendar.jpg

pdf-2.png2023 Interim Results Earnings Call


Dear Investors:

Hua Medicine (2552.HK) cordially invites you or your representative to attend the conference call for the Company’s 2023 interim results, which will be held 9:00 AM HKT, August 25, 2023 (Friday).

During the conference call, management will provide a review of the Company’s interim financial results in 2023, business updates, as well as address plans for the future.

Details of the earnings call are as follows:


Date:

August 25, 2023

Time:

Login starts: 8:45AM HKT
Meeting starts: 9:00AM HKT

Duration:

Approximately 50mins (including Q&A session)

Language:

English

Management:

Dr. Li Chen, Founder and CEO
Mr. George Lin, EVP & Chief Strategy Officer

Moderator:

Christopher Lui, China Healthcare Analyst, Jefferies

RSVP:

Join zoom webinar:
Hua Medicine Earnings Call
*Please input your personal particulars and you will be directed to the page with connection details of this webinar.


About Hua Medicine

Hua Medicine is an innovative drug development and commercialization company based in Shanghai, China, focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care. As Hua Medicine's cornerstone product (dorzagliatin tablets), targeting the glucose sensor, glucokinase, restores glucose sensitivity in T2D patients and stabilizes the imbalance of blood glucose levels in patients, it has been approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD) and Type 2 diabetes (i.e., diabetes kidney disease), no dose adjustment is required. Hua Medicine will partner with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing (华堂宁®) in China, benefiting diabetic patients and their families. HuaTangNing (华堂宁®) has also demonstrated its potential of achieving diabetes remission in clinical studies to help millions of diabetic patients around the world.

Focus Us
Copyright © 2024  Hua Medicine (Shanghai) Co., Ltd.    互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备14036654号-1  beiantubiao.png 沪公网安备 31011502013809号  Privacy Statement  Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
Accept
x